NWBS Northw.Bio Regs

 

TIDMNWBS TIDMNWBT 
 
RNS Number : 7480M 
Northwest Biotherapeutics Inc 
04 February 2009 
 

 
 
Northwest Biotherapeutics, Inc. 
("NWBT", "Northwest" or the "Company") 
 
 
 
 
 
 
Financing Update 
 
 
 
 
 
 
BETHESDA, MD - 6 November 2008 - Northwest Biotherapeutics, Inc. (AIM: NWBS and 
NWBT; OTC BB: NWBO), today announces that it is at an advanced stage of 
discussions with a potential provider of finance to the Company. 
 
 
The Company will need to raise additional capital to fund its clinical trials 
and other operating activities and to repay indebtedness in due course. 
Shareholders should be aware that if the Company's capital raising efforts are 
unsuccessful, this will have a material adverse effect on the Company's 
financial position and operations. 
 
 
A further announcement will be made in due course as appropriate. 
 
 
 
 
About NWBT 
 
 
Northwest Biotherapeutics, Inc. is a biotechnology company focused on developing 
immunotherapy products that treat cancers more effectively than current 
treatments, with limited toxicity, on a cost-effective basis. The Company has 
two broad platform technologies: dendritic cell-based vaccines, and therapeutic 
antibodies. The Company is currently conducting a large clinical trial in 
Glioblastoma multiforme, which is designed and powered to serve as a pivotal 
trial. The Company has also received clearance from the FDA for a large Phase 
III trial in prostate cancer, and clearance from the FDA for Phase I trials in 
five other cancers. The Company has started, and is currently enrolling patients 
in, a Phase I/II trial with DCVax for recurrent ovarian cancer. The Company also 
has a second technology platform, involving monoclonal antibodies to CXCR4, 
which is at the late pre-clinical development stage. 
 
 
For further information, please visit the company web site at www.nwbio.com. 
 
 
Disclaimer 
Statements made in this news release that are not historical facts, 
including statements concerning the Company's plans to move its programs 
forward, statements regarding the Company's clinical trials and other business 
development activities, and statements regarding its fundraising activities, are 
forward-looking statements within the meaning of the Private Securities 
Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," 
and similar expressions are intended to identify forward-looking statements. 
Actual results may differ materially from those projected in any forward-looking 
statement. Specifically, there are a number of important factors that could 
cause actual results to differ materially from those anticipated, such as risks 
and uncertainties regarding the Company's ability to secure additional financing 
or raise additional capital, risks related to the Company's ability to enroll 
patients in its clinical trials and complete the trials on a timely basis, the 
uncertainty of the clinical trials process, uncertainties about the timely 
performance of third parties, and whether the Company's products will 
demonstrate safety and efficacy. Additional information on these and other 
factors, which could affect the Company's results, is included in its Securities 
and Exchange Commission ("SEC") filings, including in the Risk Factors section 
of the Company's Annual Report on Form 10-K for the year ended December 31, 2007 
and in its recently filed Form S-1. Finally, there may be other factors not 
mentioned above or included in the Company's SEC filings or recently filed Form 
S-1 that may cause actual results to differ materially from those projected in 
any forward-looking statement. You should not place undue reliance on any 
forward-looking statements. The Company assumes no obligation to update any 
forward-looking statements as a result of new information, future events or 
developments, except as required by securities laws. 
 
 
  For further information, please contact: 
 
 
+----------------------------------------------------------------+----------------------+ 
| Northwest Biotherapeutics, Inc.                                |                      | 
+----------------------------------------------------------------+----------------------+ 
| Alton L. Boynton, Chief Executive Officer                      | +1 240 497 9024      | 
+----------------------------------------------------------------+----------------------+ 
|                                                                |                      | 
+----------------------------------------------------------------+----------------------+ 
| Buchanan Communications                                        |                      | 
+----------------------------------------------------------------+----------------------+ 
| Lisa Baderoon (lisab@buchanan.uk.com) / Mary-Jane Johnson /    | +44 (0)20 7466 5000  | 
| Catherine Breen                                                |                      | 
+----------------------------------------------------------------+----------------------+ 
|                                                                |                      | 
+----------------------------------------------------------------+----------------------+ 
| Collins Stewart Europe Limited                                 |                      | 
+----------------------------------------------------------------+----------------------+ 
| Adrian Hadden/ Adam Cowen                                      | +44 (0)20 7523 8350  | 
+----------------------------------------------------------------+----------------------+ 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCTJMMTMMBMTML 
 

Northw.Bio Regs (LSE:NWBS)
Historical Stock Chart
From May 2024 to Jun 2024

Northw.Bio Regs (LSE:NWBS)
Historical Stock Chart
From Jun 2023 to Jun 2024